Clinical research

DOI: 10.4244/EIJ-D-23-00361

Safety and efficacy of the DragonFly system for transcatheter valve repair of degenerative mitral regurgitation: one-year results of the DRAGONFLY-DMR trial

Jian'an Wang1, MD, PhD; Xianbao Liu1, MD, PhD; Zhaoxia Pu1, MD; Mao Chen2, MD, PhD; Zhenfei Fang3, MD, PhD; Jun Jin4, MD; Jianzhen Dong5, MD, PhD; Yansong Guo6, MD, PhD; Biao Cheng7, MD; Jiancheng Xiu8, MD, PhD; Jianfang Luo9, MD; Yida Tang10, MD, PhD; Yan Wang11, MD, PhD; Xiaomen Chen12, MD, PhD; Gejun Zhang13, MD, PhD; Yibing Shao14, MD, PhD; Guangyuan Song15, MD, PhD; Lang Hong16, MD; Hong Jiang17, MD, PhD; Yangqin Wu18, MD, PhD; Yiqiang Yuan19, MD; Lianglong Chen20, MD, PhD; Ben He21, MD, PhD; Jingfeng Wang22, MD, PhD; Kai Xu23, MD; Yining Yang24, MD, PhD; Daxin Zhou25, MD, PhD; Qi Zhang26, MD, PhD; Yi Li27, MD; Kangmu Ma28, MD, PhD; Yat-Yin Lam29, MD; Yaling Han23, MD, PhD; Junbo Ge25, MD, PhD; D. Scott Lim30, MD; for the DRAGONFLYDMR Pivotal Trial Investigators

Abstract

BACKGROUND: Severe degenerative mitral regurgitation (DMR) can cause a poor prognosis if left untreated. For patients considered at prohibitive surgical risk, transcatheter edge-to-edge repair (TEER) has become an accepted alternative therapy. The DragonFly transcatheter valve repair system is an innovative evolution of the mitral TEER device family to treat DMR.

AIMS: Herein we report on the DRAGONFLY-DMR trial (ClinicalTrials.gov: NCT04734756), which was a prospective, single-arm, multicentre study on the safety and effectiveness of the DragonFly system.

METHODS: A total of 120 eligible patients with prohibitive surgical risk and DMR ≥3+ were screened by a central eligibility committee for enrolment. The study utilised an independent echocardiography core laboratory and clinical event committee. The primary endpoint was the clinical success rate, which measured freedom from all-cause mortality, mitral valve reintervention, and mitral regurgitation (MR) >2+ at 1-year follow-up.

RESULTS: At 1 year, the trial successfully achieved its prespecified primary efficacy endpoint, with a clinical success rate of 87.5% (95% confidence interval: 80.1-92.3%). The rates of major adverse events, all-cause mortality, mitral valve reintervention, and heart failure hospitalisation were 9.0%, 5.0%, 0.8%, and 3.4%, respectively. MR ≤2+ was 90.4% at 1 month and 92.0% at 1 year. Over time, left ventricular reverse remodelling was observed (p<0.05), along with significant improvements in the patients’ functional and quality-of-life outcomes, shown by an increase in the New York Heart Association Class I/II from 32.4% at baseline to 93.6% at 12 months (p<0.001) and increased Kansas City Cardiomyopathy Questionnaire (KCCQ) score of 31.1±18.2 from baseline to 12 months (p<0.001).

CONCLUSIONS: The DRAGONFLY-DMR trial contributes to increasing evidence supporting the safety and efficacy of TEER therapy, specifically the DragonFly system, for treating patients with chronic symptomatic DMR 3+ to 4+ at prohibitive surgical risk.

Sign in to read
the full article

Forgot your password?
No account yet?
Sign up for free!

Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com

Volume 20 Number 4
Feb 19, 2024
Volume 20 Number 4
View full issue


Key metrics

Suggested by Cory

Image – Interventional flashlight

10.4244/EIJ-D-23-00302 Dec 18, 2023
First-in-human experience with a novel transcatheter direct annuloplasty system for severe atrial functional mitral regurgitation
Zhu Z et al

10.4244/EIJV10SUA16 Sep 27, 2014
Medtronic transcatheter mitral valve replacement
Piazza N et al
free

EXPERT REVIEW

10.4244/EIJ-D-18-00511 Sep 7, 2018
Transcatheter mitral valve repair: review of the clinical evidence
Taramasso M et al
free

EXPERT REVIEW

10.4244/EIJ-D-17-00673 Sep 24, 2017
Transcatheter mitral valve replacement: device landscape and early results
Patel A and Bapat VN
free

10.4244/EIJV9I5A102 Sep 27, 2013
MitraClip® via direct right atrial access in case of a missing inferior vena cava
Frerker C et al
free

10.4244/EIJV8SQA10 Sep 30, 2012
Transcatheter mitral valve interventions: current status and future perspective
Feldman T and Ali O
free

10.4244/EIJV13I3A37 Jun 20, 2017
An old dichotomy in the space(r) age
Khamis R and Mylotte D
free
Trending articles
152.9

Clinical research

10.4244/EIJ-D-20-01125 Oct 20, 2021
An upfront combined strategy for endovascular haemostasis in transfemoral transcatheter aortic valve implantation
Costa G et al
free
47.8

NEW INNOVATION

10.4244/EIJ-D-15-00467 Feb 20, 2018
Design and principle of operation of the HeartMate PHP (percutaneous heart pump)
Van Mieghem NM et al
free
39.1

Clinical research

10.4244/EIJ-D-22-00558 Feb 6, 2023
Permanent pacemaker implantation and left bundle branch block with self-expanding valves – a SCOPE 2 subanalysis
Pellegrini C et al
free
X

The Official Journal of EuroPCR and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)

EuroPCR EAPCI
PCR ESC
Impact factor: 7.6
2023 Journal Citation Reports®
Science Edition (Clarivate Analytics, 2024)
Online ISSN 1969-6213 - Print ISSN 1774-024X
© 2005-2024 Europa Group - All rights reserved